Encouraging Interim Results of ASN-002 Treatment

November 8th 2016

Ascend announces encouraging Phase I/IIa interim results of ASN-002 treatment of Nodular Basal Cell Carcinoma with 100% overall objective response rate for medium and high dose cohorts.

Press Release: ASN-002 Treatment Interim Results

News